Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

10 terminated/withdrawn out of 55 trials

Success Rate

70.6%

-16.0% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

67%

16 of 24 completed trials have results

Key Signals

7 recruiting16 with results5 withdrawn

Enrollment Performance

Analytics

Phase 1
25(46.3%)
Phase 2
21(38.9%)
N/A
6(11.1%)
Phase 3
1(1.9%)
Early Phase 1
1(1.9%)
54Total
Phase 1(25)
Phase 2(21)
N/A(6)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials
NCT03803553Phase 3Active Not Recruiting

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Role: collaborator

NCT03875287Phase 1Active Not Recruiting

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Role: collaborator

NCT05918640Phase 1Recruiting

Lurbinectedin in FET-Fused Tumors

Role: collaborator

NCT06070870Not ApplicableRecruiting

Health Education Approach to Lung Screening

Role: collaborator

NCT05995821Recruiting

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Role: collaborator

NCT03220477Phase 1Active Not Recruiting

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Role: collaborator

NCT03410030Phase 1Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Role: collaborator

NCT03762590Not ApplicableActive Not Recruiting

GENetic Education Risk Assessment and TEsting Study

Role: collaborator

NCT05013216Phase 1Recruiting

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Role: collaborator

NCT03602157Phase 1Active Not Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Role: collaborator

NCT03415854Phase 2Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Role: collaborator

NCT04262154Phase 2Active Not Recruiting

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Role: collaborator

NCT05812274Not ApplicableTerminated

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Role: collaborator

NCT06015659Phase 2Active Not Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Role: collaborator

NCT04434040Phase 2Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Role: collaborator

NCT05886764Not ApplicableActive Not Recruiting

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Role: collaborator

NCT03568422Phase 1Active Not Recruiting

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Role: collaborator

NCT04469556Phase 2Completed

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Role: collaborator

NCT06208657Phase 1Recruiting

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Role: collaborator

NCT04995003Phase 1Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Role: collaborator